Please provide your email address to receive an email when new articles are posted on . Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) is an option after any intraocular surgery ...

Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances.

Cataract surgery remains one of the most frequently performed ophthalmic procedures worldwide, with continual refinements in surgical methods and intraocular lens (IOL) technology contributing to ...

FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...

The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical trial designed to evaluate the safety and efficacy of TRIESENCE in patients undergoing cataract ...

Most people have a relative, friend or neighbor who has had to deal with a cataract. Nearly 24.5 million Americans age 40 or older are affected by cataracts, and it’s the leading cause of blindness ...

In response to this education gap, Eye Surgery Today was founded by nationally recognized key opinion leaders (KOLs) to make high-quality eye surgery education accessible to everyone.

Program Stipend: $47,545 (13-month program). Eligible for health benefits and professional liability insurance included. A $500 stipend for continuing education is provided. The program begins on the ...

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a ...

Q: What is the payment policy for an Astigmatism-Correcting Intraocular Lens (A-C-IOL) inserted following removal of a cataract in a hospital or ambulatory surgical center? CMS: The payment policy for ...